172 related articles for article (PubMed ID: 37191958)
1. Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.
An MH; Kim MS; Kim C; Noh TI; Joo KJ; Lee DH; Yi KH; Kwak JW; Hwang TH; Park RW; Kang SH
JAMA Netw Open; 2023 May; 6(5):e2313667. PubMed ID: 37191958
[TBL] [Abstract][Full Text] [Related]
2. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
JAMA Oncol; 2022 Jul; 8(7):1019-1026. PubMed ID: 35587340
[TBL] [Abstract][Full Text] [Related]
3. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
4. The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada.
Wissing MD; O'Flaherty A; Dragomir A; Tanguay S; Kassouf W; Aprikian AG
Clin Genitourin Cancer; 2021 Aug; 19(4):371-371.e9. PubMed ID: 33676834
[TBL] [Abstract][Full Text] [Related]
5. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
6. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort.
Dekalo S; McArthur E; Campbell J; Ordon M; Power N; Welk B
Urol Oncol; 2023 Jan; 41(1):50.e11-50.e17. PubMed ID: 36319553
[TBL] [Abstract][Full Text] [Related]
7. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
8. 5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.
Del Giudice F; Belladelli F; Glover F; Basran S; Li S; Mulloy E; Pradere B; Soria F; Krajewski W; Nair R; Muncey W; Seranio N; Eisenberg ML
World J Urol; 2023 Oct; 41(10):2783-2791. PubMed ID: 37548746
[TBL] [Abstract][Full Text] [Related]
9. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
[TBL] [Abstract][Full Text] [Related]
10. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.
Mäkelä VJ; Kotsar A; Tammela TLJ; Murtola TJ
J Urol; 2018 Oct; 200(4):743-748. PubMed ID: 29730200
[TBL] [Abstract][Full Text] [Related]
11. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
[TBL] [Abstract][Full Text] [Related]
12. Association of Open vs Robot-Assisted Radical Cystectomy With Mortality and Perioperative Outcomes Among Patients With Bladder Cancer in Sweden.
Mortezavi A; Crippa A; Kotopouli MI; Akre O; Wiklund P; Hosseini A
JAMA Netw Open; 2022 Apr; 5(4):e228959. PubMed ID: 35482309
[TBL] [Abstract][Full Text] [Related]
13. Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?
McMartin C; Lacombe L; Fradet V; Fradet Y; Lodde M; Toren P
Clin Genitourin Cancer; 2019 Dec; 17(6):e1122-e1128. PubMed ID: 31594737
[TBL] [Abstract][Full Text] [Related]
14. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
15. Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis.
Baboudjian M; Gondran-Tellier B; Dariane C; Fiard G; Fromont G; Rouprêt M; Ploussard G
JAMA Oncol; 2023 Jun; 9(6):847-850. PubMed ID: 37079318
[TBL] [Abstract][Full Text] [Related]
16. 5α-reductase inhibitors impact prognosis of urothelial carcinoma.
Wang CS; Li CC; Juan YS; Wu WJ; Lee HY
BMC Cancer; 2020 Sep; 20(1):872. PubMed ID: 32917158
[TBL] [Abstract][Full Text] [Related]
17. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
18. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
Murtola TJ; Kujala PM; Tammela TL
Prostate; 2013 Jun; 73(9):923-31. PubMed ID: 23334943
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of 5-α reductase inhibitor and androgen deprivation therapy in bladder cancer incidence, recurrence, and survival: a meta-analysis and systemic review.
Kim A; Kim MS; Ahn JH; Choi WS; Park HK; Kim HG; Paick SH
Aging Male; 2020 Dec; 23(5):971-978. PubMed ID: 31724468
[TBL] [Abstract][Full Text] [Related]
20. Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy.
Hong SK; Oh JJ; Lee S; Lee HM; Byun SS; Choe G; Lee SE
Prostate; 2012 Aug; 72(11):1187-92. PubMed ID: 22161951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]